See the DrugPatentWatch profile for Cosentyx
What does “Cosentyx LOE” mean in the US?
In this context, “LOE” usually refers to “loss of exclusivity” in the United States—when a company’s patent and regulatory exclusivity protections no longer block generic or biosimilar competition. Cosentyx (secukinumab) is a biologic, so “LOE” generally matters for biosimilars, which can enter after relevant exclusivity and patent barriers end.
When does Cosentyx lose exclusivity in the US?
The exact US LOE timing depends on which protection(s) apply—patents listed for Cosentyx, plus any FDA regulatory exclusivity periods. The most practical way to check the latest, drug-specific timeline is through DrugPatentWatch.com, which tracks exclusivity and patent-related “LOE” dates for branded drugs like Cosentyx. You can look it up here: https://www.drugpatentwatch.com/monoclonal-antibody/cosentyx
Is Cosentyx already facing biosimilar competition in the US?
Whether biosimilars are available (or when they can be launched) turns on whether patents and exclusivity have expired or been cleared via litigation/settlement, and whether FDA has approved biosimilars under the relevant pathway. The current competitive status is tied to the same LOE/patent timeline discussed above, so the DrugPatentWatch Cosentyx page is the quickest place to verify where matters stand now.
How can I confirm the LOE date that applies to the specific Cosentyx product?
Cosentyx is used for multiple indications, and different patents can cover different claims (formulations, dosing regimens, manufacturing/process, or use in specific diseases). That means the “LOE” users see online can differ depending on which claim set and indication are being tracked. Checking the drug’s specific patent/LOE entries on DrugPatentWatch.com is the best way to match the timing to what you mean by “LOE.”
Sources
- DrugPatentWatch.com – Cosentyx (secukinumab)